stockrow
Friday 6 November 2026
Export BGM’s income statement to Excel — free account
BGM Group Ltd.
BGM Healthcare Drug Manufacturers Specialty & Generic
BGM Group Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $37.9 million, up 51.1% from fiscal 2024.
8.25
0.75
−8.33%
Follow BGM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to September
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Mar ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | 23 | 50 | 46 | 50 | 57 | 65 | 46 | 25 | 38 | 121 | +6.7% | — | — | — | — | |
| Gross margin, % | — | 15.01 | 16.15 | 21.00 | 15.07 | 9.87 | 9.60 | 3.77 | 16.39 | 16.64 | 6.54 | +1.6 pt | ||||||
| EBT | — | 2 | 6 | 7 | 6 | 3 | 2 | (8) | (2) | (20) | 3 | n/m | ||||||
| EBT margin, % | — | 8.25 | 12.20 | 15.06 | 11.60 | 5.89 | 2.41 | (17.01) | (8.52) | (52.58) | 2.55 | (60.8) pt | ||||||
| Net income | — | 0 | 5 | 6 | 5 | 3 | 1 | (8) | (2) | (20) | (25) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.63 | 252.10 | 230.71 | 250.42 | 251.54 | 272.39 | 193.15 | 104.31 | 10.05 | 0.00 | +41.4% | |||||
| Earnings | — | 0.04 | 26.04 | 29.57 | 25.53 | 13.51 | 4.50 | (33.03) | (6.01) | (5.41) | 0.06 | n/m | ||||||
| Cash flow | — | 0.08 | 22.21 | (2.90) | 25.41 | 1.52 | 53.15 | 1.30 | 2.26 | (0.63) | 0.00 | n/m | ||||||
| Capex | — | 0.00 | (5.59) | (3.09) | (2.30) | (15.39) | (13.69) | (15.44) | (16.34) | (0.58) | 0.00 | n/m | ||||||
| Free cash flow | — | 0.08 | 16.62 | (5.99) | 23.11 | (13.87) | 39.46 | (14.14) | (14.08) | (1.21) | 0.00 | n/m | ||||||
| Book value | — | 0.31 | 88.70 | 113.30 | 144.35 | 249.64 | 230.84 | 184.34 | 183.26 | 103.91 | 0.00 | +106.5% | ||||||
| Shares, m | — | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | — | (24.5%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | 21.28 | 21.28 | 21.28 | 21.28 | 1,487.67 | 1,487.67 | 1,968.50 | 3,995.33 | 5,120.50 | 148.17 | 1,571.6 | |||||
| P/S | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.12) | (0.18) | (0.15) | (0.08) | (0.09) | (0.1) | ||||||
| EV/FCF | — | (0.32) | (0.32) | (0.32) | (0.32) | (0.32) | (0.86) | (2.33) | 6.15 | 1.02 | 1.16 | 0.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | 3 | 4 | (1) | 5 | 0 | 13 | 0 | 1 | (2) | (2) | n/m | |||||
| Capex | — | (2) | (1) | (1) | 0 | (3) | (3) | (4) | (4) | (2) | (7) | +4.6% | ||||||
| Free cash flow | — | 3 | 3 | (1) | 5 | (3) | 9 | (3) | (3) | (5) | (9) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 4 | 8 | 13 | 19 | 22 | 21 | 28 | 21 | 10 | 9 | +12.1% | |||||
| Net debt | — | 1 | (2) | 0 | (5) | (5) | (15) | (22) | (18) | (11) | (10) | n/m | ||||||
| Shareholders’ equity | — | 11 | 18 | 23 | 29 | 57 | 55 | 44 | 44 | 392 | 400 | +55.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | 4.24 | 31.01 | 15.54 | 12.14 | 5.11 | 1.54 | (13.44) | (2.77) | (8.19) | 0.00 | (12.4) pt | |||||
| ROIC | — | 0.00 | 23.72 | 16.83 | 12.36 | 2.87 | 3.27 | (7.28) | (1.36) | (2.06) | 0.00 | (2.1) pt | ||||||
| ROE | — | 10.65 | 35.70 | 26.42 | 19.67 | 7.37 | 1.93 | (15.67) | (3.26) | (9.15) | 0.00 | (19.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 288 | 292 | 283 | 344 | 298 | 323 | 335 | — | +2.6% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.16 | 0.17 | 0.20 | 0.19 | 0.16 | 0.08 | 0.11 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Sep 2025 · latest quarter Jan 0001 · fundamentals updated 2 Nov 2026
BGM Group Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SIGA Siga Technologies Inc. | $213.4M | — (loss-making) | 60.8× | −49.45% (below 0%: shrinking) | −66.00% (below 0%: shrinking) | −75.95% (below 0%: shrinking) | 57.17% | 33.91% | Compare |
| ADCT ADC Therapeutics SA | $209.4M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| GLAS Glass House Brands Inc. | $172.7M | — (loss-making) | — (loss-making) | −1.24% (below 0%: shrinking) | n/m | −123.36% (below 0%: shrinking) | 33.54% | (6.37%) | Compare |
| OGI Organigram Global Inc. | $131.1M | 2.0× | 1.6× | +49.28% (above 0%: growing) | n/m | −192.32% (below 0%: shrinking) | 39.16% | 5.04% | Compare |
| BGM BGM Group Ltd. | $125.7M | 148× | 44.9× | −2.59% (below 0%: shrinking) | −85.71% (below 0%: shrinking) | +3.00% (above 0%: growing) | 7.12% | 0.00% | |
| DERM Journey Medical Corporation | $121.4M | — (loss-making) | — (loss-making) | +23.33% (above 0%: growing) | n/m | −84.08% (below 0%: shrinking) | 66.81% | 2.46% | Compare |
| AKBA Akebia Therapeutics, Inc. | $117.9M | — (loss-making) | — (loss-making) | −37.20% (below 0%: shrinking) | n/m | −94.20% (below 0%: shrinking) | 82.76% | (31.06%) | Compare |
| CRDL Cardiol Therapeutics Inc. | $111.8M | — (loss-making) | — (loss-making) | — | n/m | +10.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ORGO Organogenesis | $108.1M | — (loss-making) | — (loss-making) | −69.87% (below 0%: shrinking) | n/m | −2,048.82% (below 0%: shrinking) | 51.83% | (64.87%) | Compare |
| Median of peers | $126.2M | — | — | −1.24% | — | −89.14% | 54.50% | (3.18%) |